Mario Bhatt

Mario Bhatt investigates novel therapeutic combinations for hormone receptor-positive metastatic breast cancer. His research focuses on rational combination strategies involving CDK4/6 inhibitors with PI3K, AKT, and mTOR pathway inhibitors to overcome or prevent resistance. He participates in European clinical trials evaluating abemaciclib combinations and investigates immune mechanisms that may be harnessed to enhance endocrine-based therapies. His translational studies aim to identify patient subgroups that would benefit most from specific combination approaches.